You might be looking at your screen right now, typing in "PKI" and wondering why your ticker just gave you a blank stare or redirected you to something called Revvity. It's confusing. Honestly, if you aren't glued to Bloomberg 24/7, you probably missed the massive transformation that effectively killed the PerkinElmer stock as we knew it.
Here’s the deal: PerkinElmer didn't go bankrupt. It didn't vanish into thin air. It basically performed a corporate version of mitosis.
The Great Rebrand: Why PKI is Now RVTY
Back in May 2023, the company finished a massive $2.45 billion deal with New Mountain Capital. They sold off their "applied" businesses—think food safety, environmental testing, and industrial services.
What’s left? The high-growth, high-margin stuff. We're talking life sciences and diagnostics.
Because they sold the "PerkinElmer" name along with the old divisions, the remaining company needed a new identity. They landed on Revvity (ticker: RVTY). If you see "PKI" mentioned in 2026, it's often a ghost of the past or, interestingly, the ticker for Parkland Corp on the Toronto Stock Exchange—which is a totally different beast involving a Sunoco acquisition.
Current Performance: Is Revvity Actually Doing Well?
If you're looking at the stock today, January 14, 2026, things are getting pretty spicy.
Just yesterday, the stock caught a massive bid. Why? Preliminary Q4 2025 results. Revvity basically told the market they expect revenue to hit around $772 million for the quarter, which is about 4% organic growth. That's a big deal in this sector.
The stock price reacted like a caffeinated squirrel, jumping nearly 8% in premarket trading on the news. As of right now, RVTY is hovering around the $109 to $112 range.
👉 See also: General Electric Stock Forecast: Why the Market is Bullish on GE Aerospace for 2026
The Numbers That Matter Right Now
- Market Cap: Roughly $11.78 billion to $11.9 billion depending on the daily swing.
- P/E Ratio: It's high—sitting around 52x. This tells you investors are paying a premium for that expected growth.
- Dividend: Don’t buy this for the income. The yield is tiny, roughly 0.25% to 0.28%.
- 52-Week Range: It’s been a ride, swinging from a low of about $81 up to $128.
The AI Catalyst Most People Are Missing
Everyone talks about Revvity as a "diagnostics" company. That's boring. What's actually interesting is their January 9th announcement about a deep-collaboration with Eli Lilly.
They are deploying AI in drug discovery.
Basically, they are using their massive data sets and "Signals" software to help Lilly find new drug candidates faster. In a world where every biotech firm is trying to trim the fat off their R&D budgets, this kind of tech is the real value driver. It moves the needle more than just selling another lab instrument.
What Most Investors Get Wrong
People see the 3-year or 5-year charts for "PerkinElmer" and see a sea of red—down maybe 30%. They think the company is failing.
That’s a mistake.
Those old charts include the bulkier, lower-margin businesses that are no longer part of the equation. The "new" Revvity is designed to be lean. They are targeting adjusted EPS growth of 13% to 15% annually.
Is it perfect? No. The debt load is still a bit of a "boatload" (to use the technical term). They've been using cash to buy back shares—over $205 million in Q3 2025 alone—which is great for shareholders, but it means they aren't necessarily hoarding cash for a rainy day.
🔗 Read more: Converting 280 HKD to USD: Why the Math Isn't Always What You Think
The China Factor
You can't talk about this stock without mentioning China. About a third of the diagnostics market for companies like this often ties back to Chinese hospital spending.
Management has been upfront: China is a headwind. They expect those pressures to stick around through at least the first half of 2026. If you're a bull, you're betting that the stability in their software and life sciences divisions can carry the weight until the Chinese market stabilizes.
Expert Insights on Valuation
Most analysts are currently leaning toward a "Buy" or "Hold." The median price target is sitting around $117, though the real optimists see it hitting $145 if the AI-driven product innovation actually starts scaling.
Actionable Steps for Investors
- Stop Tracking PKI: If your portfolio tracker still says PKI, delete it. You need to follow RVTY to get accurate data on the business formerly known as PerkinElmer.
- Watch the $109 Pivot: Technical traders are looking at $109 as a key support level. If it holds above that, the momentum from the Q4 beat might carry it toward that $128 high.
- Monitor the Debt-to-Equity: Keep an eye on those quarterly balance sheets. The shift to a "high-margin" model only works if interest payments don't eat the lunch.
- Check the Eli Lilly Updates: Any news regarding the success of their AI discovery platform is likely to trigger more volatility than a standard earnings report.
The old PerkinElmer is gone. What's left is a specialized, tech-heavy healthcare company that is finally starting to prove its "new" self to a skeptical market. It's a growth play now, not a value trap.